HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate FDA User Fee Bill’s Mandatory Supplement Listing Provision Unites Industry In Opposition

Executive Summary

Senate HELP Committee didn’t add amendments to user fee bill to protect confidential information and prevent FDA over-regulation in an MPL program, trade groups say. MPL proponents join opponents in saying language in S.4348 isn’t the answer.

You may also be interested in...



No Longer Draft, Senate Mandatory Supplement Registration Bill Gets Flood Of Opposition

Some stakeholders have supported mandatory listing but they join opponents questioning legislation also authorizing FDA to prohibit sales of products compliant with manufacturing and labeling regulations but deficient, incomplete or late with registration information required for the agency.

US Supplement Industry Capitol Hill Champion, Pivotal Drug Legislation Author Orrin Hatch Dies

DSHEA, legislation Congress passed in 1994 establishing framework for FDA’s oversight of supplement manufacturing and marketing, doesn’t bear Hatch’s name. But in US consumer health products industry, his name is probably more frequently linked with DSHEA than with pivotal drug legislation he co-authored.

Supplement OWL Progress: Mirror For Industry Support For Transparency, Mandatory Registration?

Advisory board for CRN-operated Supplement OWL recently reached out to industry for “ultimate reason” of recruiting participation. “Transparency has never been more important and this registry is a demonstration of this industry’s commitment to candor and honesty with our regulators, retailers and consumers,” they say.

Topics

Latest News
UsernamePublicRestriction

Register

RS152640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel